38 000 MW Antigen-specific Major Histocompatibility Complex Class I Restricted Interferon-gamma-secreting CD8+ T Cells in Healthy Contacts of Tuberculosis
Overview
Affiliations
CD8+ T lymphocytes are required to protect mice against Mycobacterium tuberculosis, although in early infection the mechanism appears not to be via perforin or granzyme-mediated lysis of the infected target, and may be via interferon-gamma (IFN-gamma) production. We therefore investigated whether CD8+ T cells specific for the immunoprotective 38 000 MW antigen of M. tuberculosis could be detected in infected humans. Using a recombinant vaccinia virus expressing the 38 000 MW antigen of M. tuberculosis (rV38) and a control vaccinia virus (rVras) we demonstrated that both viruses stimulated IFN-gamma production from freshly isolated peripheral blood mononuclear cells (PBMC) in a 36-hr enzyme-linked immunospot assay. Cell depletion and antibody blockade established that the bulk of the 38 000 MW antigen-specific IFN-gamma response was mediated by CD8+, major histocompatibility complex class I-restricted T cells, whereas the anti-vaccinia virus response was predominantly mediated by CD4+ T cells. In further evaluations PBMC from all seven healthy tuberculosis-exposed contacts had a 38 000 MW antigen-specific IFN-gamma response, whereas seven patients with untreated sputum-positive pulmonary tuberculosis had very low levels of 38 000 antigen-specific IFN-gamma-producing cells. These preliminary observations demonstrate the utility of recombinant vaccinia viruses in restimulating freshly isolated CD4+ and CD8+ T cells. The bias towards a higher frequency of IFN-gamma-producing CD8+ T cells in contacts rather than patients may indicate a protective role for CD8+ cells in human tuberculosis.
Jiang Q, Zhang J, Chen X, Xia M, Lu Y, Qiu W J Biomed Res. 2013; 27(5):406-20.
PMID: 24086174 PMC: 3783826. DOI: 10.7555/JBR.27.20120114.
Reducing the activity and secretion of microbial antioxidants enhances the immunogenicity of BCG.
Sadagopal S, Braunstein M, Hager C, Wei J, Daniel A, Bochan M PLoS One. 2009; 4(5):e5531.
PMID: 19436730 PMC: 2677452. DOI: 10.1371/journal.pone.0005531.
Wilkinson K, Simsova M, Scholvinck E, Sebo P, Leclerc C, Vordermeier H Infect Immun. 2005; 73(5):2991-8.
PMID: 15845506 PMC: 1087377. DOI: 10.1128/IAI.73.5.2991-2998.2005.
Al-Attiyah R, Shaban F, Wiker H, Oftung F, Mustafa A Infect Immun. 2003; 71(4):1953-60.
PMID: 12654813 PMC: 152036. DOI: 10.1128/IAI.71.4.1953-1960.2003.
Fonseca D, van Engelen M, Kraaijeveld C, Snippe H, Verheul A Infect Immun. 2001; 69(8):4839-45.
PMID: 11447158 PMC: 98572. DOI: 10.1128/IAI.69.8.4839-4845.2001.